Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ec7596b0b0bd4d8792261cf113de7428 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ec7596b0b0bd4d8792261cf113de7428 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ec7596b0b0bd4d8792261cf113de74282021-11-18T07:35:02ZUnmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.1932-620310.1371/journal.pone.0027126https://doaj.org/article/ec7596b0b0bd4d8792261cf113de74282011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22073272/?tool=EBIhttps://doaj.org/toc/1932-6203Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the risk of adverse side effects, which are usually associated with long-term pharmacological interventions. Our previous study in mice fed high-fat diet indicated additivity in preservation of insulin sensitivity and in amelioration of major metabolic syndrome phenotypes by the combination treatment using n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and rosiglitazone, i.e. an anti-diabetic drug of the thiazolidinedione (TZD) family. We investigated here whether pioglitazone, a TZD-drug in clinical use, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice (C57BL/6N) were fed an obesogenic corn oil-based high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with 10 mg rosiglitazone/kg diet; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with 50 mg pioglitazone/kg diet; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites were evaluated using a targeted metabolomics approach. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin, with pioglitazone showing better effectiveness. The beneficial effects of TZDs were further augmented by the combination treatments. cHF+F+ROSI but not cHF+F+PIO counteracted development of obesity, in correlation with inducibility of fatty acid β-oxidation, as revealed by the metabolomic analysis. By contrast, only cHF+F+PIO eliminated hepatic steatosis and this treatment also reversed insulin resistance in dietary obese mice. Our results reveal differential effects of rosiglitazone and pioglitazone, unmasked in the combination treatment with n-3 LC-PUFA, and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient's therapy.Vladimir KusPavel FlachsOndrej KudaKristina BardovaPetra JanovskaMichaela SvobodovaZuzana Macek JilkovaMartin RossmeislRui Wang-SattlerZhonghao YuThomas IlligJan KopeckyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 11, p e27126 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Vladimir Kus Pavel Flachs Ondrej Kuda Kristina Bardova Petra Janovska Michaela Svobodova Zuzana Macek Jilkova Martin Rossmeisl Rui Wang-Sattler Zhonghao Yu Thomas Illig Jan Kopecky Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| description |
Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the risk of adverse side effects, which are usually associated with long-term pharmacological interventions. Our previous study in mice fed high-fat diet indicated additivity in preservation of insulin sensitivity and in amelioration of major metabolic syndrome phenotypes by the combination treatment using n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and rosiglitazone, i.e. an anti-diabetic drug of the thiazolidinedione (TZD) family. We investigated here whether pioglitazone, a TZD-drug in clinical use, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice (C57BL/6N) were fed an obesogenic corn oil-based high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with 10 mg rosiglitazone/kg diet; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with 50 mg pioglitazone/kg diet; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites were evaluated using a targeted metabolomics approach. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin, with pioglitazone showing better effectiveness. The beneficial effects of TZDs were further augmented by the combination treatments. cHF+F+ROSI but not cHF+F+PIO counteracted development of obesity, in correlation with inducibility of fatty acid β-oxidation, as revealed by the metabolomic analysis. By contrast, only cHF+F+PIO eliminated hepatic steatosis and this treatment also reversed insulin resistance in dietary obese mice. Our results reveal differential effects of rosiglitazone and pioglitazone, unmasked in the combination treatment with n-3 LC-PUFA, and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient's therapy. |
| format |
article |
| author |
Vladimir Kus Pavel Flachs Ondrej Kuda Kristina Bardova Petra Janovska Michaela Svobodova Zuzana Macek Jilkova Martin Rossmeisl Rui Wang-Sattler Zhonghao Yu Thomas Illig Jan Kopecky |
| author_facet |
Vladimir Kus Pavel Flachs Ondrej Kuda Kristina Bardova Petra Janovska Michaela Svobodova Zuzana Macek Jilkova Martin Rossmeisl Rui Wang-Sattler Zhonghao Yu Thomas Illig Jan Kopecky |
| author_sort |
Vladimir Kus |
| title |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| title_short |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| title_full |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| title_fullStr |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| title_full_unstemmed |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| title_sort |
unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/ec7596b0b0bd4d8792261cf113de7428 |
| work_keys_str_mv |
AT vladimirkus unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT pavelflachs unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT ondrejkuda unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT kristinabardova unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT petrajanovska unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT michaelasvobodova unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT zuzanamacekjilkova unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT martinrossmeisl unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT ruiwangsattler unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT zhonghaoyu unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT thomasillig unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet AT jankopecky unmaskingdifferentialeffectsofrosiglitazoneandpioglitazoneinthecombinationtreatmentwithn3fattyacidsinmicefedahighfatdiet |
| _version_ |
1718423258519306240 |